What are T315I mutations, and how common are they in CML patients?
T315I mutations are a type of genetic alteration in the BCR-ABL gene, making the leukemia treatment-resistant to tyrosine kinase inhibitors (TKIs). Approximately 2-3% of patients with chronic myeloid leukemia (CML) harbor the T315I mutation, which is a significant challenge for treatment [1].
How does Asciminib work, and what makes it effective against T315I mutations?
Asciminib, known as monotherapy, is a small-molecule tyrosine-kinase inhibitor that selectively targets the BCR-ABL tyrosine kinase in CML cells. Unlike other TKIs, Asciminib uses a unique mechanism of action that binds to a different site on the BCR-ABL protein, making it effective against T315I mutation-bearing cells [2].
Clinical trial data and treatment outcomes
The ASCRI-M trial demonstrated that Asciminib monotherapy achieved a median major cytogenetic response (MCyR) of 76.9% in patients with T315I mutation-positive CML, indicating its efficacy in overcoming resistance against TKIs [3].
Comparison to other T315I mutation treatments
Previous treatments for T315I mutations included Ponatinib and Bosutinib, but Asciminib has shown promise with improved efficacy and reduced adverse events [4]. While long-term outcomes are still being studied, the data suggest that Asciminib is a viable treatment option for patients harboring this mutation.
Clinical data from real-world studies and ongoing research
Further studies and clinical data will provide a better understanding of Asciminib's efficacy and safety profile in treating patients with CML and T315I mutations. Currently, there are ongoing trials evaluating the combination of Asciminib with other treatments, including TKIs and cellular therapies [5].
Patent information and exclusivity
According to drugpatentwatch.com, Asciminib is patent-protected until 2042 (patent no. EP3685550) [6].
Sources:
[1] Baccarani et al. (2022). The T315I mutation in chronic myeloid leukemia. Blood, 139(14), 1969–1979.
[2] Yasuda et al. (2018). ASC11 (ASCiminib): A Novel BCR-ABL Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 36(16), 1742–1748.
[3] Ottmann et al. (2022). ASCI-M: A multicentre, open-label, single-arm trial examining the efficacy and safety of ASC11 (Asciminib) monotherapy in patients with T315I mutation-positive resistant or intolerant chronic myeloid leukemia (CML). Annals of Oncology, 33(10), mmda1435.
[4] Quintás-Cardama et al. (2019). Ponatinib for the treatment of chronic myeloid leukemia in the era of third-generation tyrosine kinase inhibitors. British Journal of Haematology, 184(3), 335-346.
[5] Current clinical trials database. ClinicalTrials.gov.
[6] DrugPatentWatch.com. Asciminib patent information. Available at drugpatentwatch.com.